Edwards PASCAL CLASP IID/IIF Pivotal Clinical Trial

Description

To establish the safety and effectiveness of the Edwards PASCAL Transcatheter Valve Repair System in patients with degenerative mitral regurgitation (DMR) who have been determined to be at prohibitive risk for mitral valve surgery by the Heart Team, and in patients with functional mitral regurgitation (FMR) on guideline directed medical therapy (GDMT)

Conditions

Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation

Talk to us

Study Overview

On this page

Study Details

Study overview

To establish the safety and effectiveness of the Edwards PASCAL Transcatheter Valve Repair System in patients with degenerative mitral regurgitation (DMR) who have been determined to be at prohibitive risk for mitral valve surgery by the Heart Team, and in patients with functional mitral regurgitation (FMR) on guideline directed medical therapy (GDMT)

Edwards PASCAL TrAnScatheter Valve RePair System Pivotal Clinical Trial (CLASP IID/IIF): A Prospective, Multicenter, Randomized, Controlled Pivotal Trial to Evaluate the Safety and Effectiveness of Transcatheter Mitral Valve Repair With the Edwards PASCAL Transcatheter Valve Repair System Compared to Abbott MitraClip in Patients With Mitral Regurgitation

Edwards PASCAL CLASP IID/IIF Pivotal Clinical Trial

Condition
Degenerative Mitral Valve Disease
Intervention / Treatment

-

Contacts and Locations

Birmingham

The University of Alabama at Birmingham, Birmingham, Alabama, United States, 35233

Phoenix

Banner University Medical Center, Phoenix, Arizona, United States, 85006

Phoenix

Abrazo Arizona Heart Hospital, Phoenix, Arizona, United States, 85016

Phoenix

Arizona Cardiovascular Research Center, Phoenix, Arizona, United States, 85016

Tucson

TMC Healthcare, Tucson, Arizona, United States, 85712

La Jolla

Scripps Memorial Hospital La Jolla, La Jolla, California, United States, 92071

Los Angeles

PIH Health Good Samaritan Hospital, Los Angeles, California, United States, 90017

Los Angeles

Cedars Sinai Medical Center, Los Angeles, California, United States, 90048

Orange

St. Joseph Hospital, Orange, California, United States, 92868

Orange

UC Irvine, Orange, California, United States, 92868

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Eighteen (18) years of age or older
  • * Patient is able and willing to give informed consent and follow protocol procedures, and comply with follow-up visit requirements.
  • * Patient is determined to be at prohibitive risk for mitral valve surgery by the heart team (CLASP IID cohort only).
  • * Patient is on stable heart failure medications/Guideline Directed Medical Therapy (CLASP IIF cohort only)
  • * Patient is determined to be a candidate for transcatheter mitral valve repair by the heart team for both PASCAL and MitraClip
  • * Mitral regurgitation (3+ to 4+) by echo
  • * Suitable valve and regurgitant jet morphology
  • * Elevated corrected BNP \> 400 pg/ml or corrected NT-pro BNP of \> 900 pg/ml or heart failure hospitalization within the past 12 months (CLASP IIF cohort only)
  • * LVEF ≥ 20% (and ≤ 50%; CLASP IIF cohort only)
  • * Patient in whom a TEE is contraindicated or screening TEE is unsuccessful
  • * Mitral valve anatomy which may preclude proper PASCAL or MitraClip access, use and/or deployment or sufficient reduction in mitral regurgitation
  • * Patient with refractory heart failure requiring advanced intervention (i.e. left ventricular assist device, Status ≤5 heart transplantation) (ACC/AHA Stage D heart failure)
  • * Clinically significant, untreated coronary artery disease
  • * Recent stroke
  • * Other severe valve disorders requiring intervention
  • * Need for emergent or urgent surgery for any reason or any planned cardiac surgery within the next 12 months
  • * Any prior mitral valve surgery or transcatheter mitral valve procedure (excluding chordal replacement or surgical annuloplasty repair)
  • * Severe tricuspid regurgitation or tricuspid valve disease requiring surgery
  • * Active rheumatic heart disease or rheumatic etiology for MR
  • * Severe aortic stenosis or regurgitation
  • * Known history of untreated, severe carotid stenosis
  • * Recent deep vein thrombosis (DVT) or pulmonary embolism (PE)
  • * Severe COPD
  • * Pregnant or planning pregnancy within next 12 months. Note: Female patients of childbearing potential need to have a negative pregnancy test performed within 14 days prior to intervention and be adherent to an accepted method of contraception
  • * Concurrent medical condition with a life expectancy of less than 12 months in the judgment of the Investigator
  • * Patient is currently participating in another investigational biologic, drug or device clinical study where the primary study endpoint was not reached at time of enrollment
  • * Other medical, social, or psychological conditions that preclude appropriate consent and follow-up, including patients under guardianship

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Edwards Lifesciences,

Scott Lim, MD, PRINCIPAL_INVESTIGATOR, University of Virginia

Robert Smith, MD, PRINCIPAL_INVESTIGATOR, The Heart Hospital Baylor Plano

Linda Gillam, MD, PRINCIPAL_INVESTIGATOR, Morristown Medical Center

Vinod Thourani, MD, PRINCIPAL_INVESTIGATOR, Piedmont Healthcare

Paul Grayburn, MD, PRINCIPAL_INVESTIGATOR, The Heart Hospital Baylor Plano

Brian K Whisenant, MD, PRINCIPAL_INVESTIGATOR, Intermountain Medical Center

Jörg Hausleiter, MD, PRINCIPAL_INVESTIGATOR, LMU München, Campus Gorsshadern

Ralph Stephan von Bardeleben, MD, PRINCIPAL_INVESTIGATOR, / Universitätsmedizin Mainz- Zentrum für Kardiologie

Study Record Dates

2030-04-30